阅读说明：本技术 一种可缓解或治疗旅行性腹泻的益生菌组合物及其应用 (Probiotic composition capable of relieving or treating travel diarrhea and application thereof ) 是由 刘晓军 马杰 包维臣 张凌宇 张建军 其木格苏都 杨慧娟 于 2020-06-03 设计创作，主要内容包括：本申请公开了一种可缓解或治疗旅行性腹泻的益生菌组合物及其应用。所述益生菌组合物包括乳双歧杆菌Probio-M8和植物乳杆菌。本申请通过跟踪检测旅行性人群的肠道中有效微生物含量,证实了该益生菌组合物,如益生菌复合固体饮料能够平衡肠道微生态,进而达到缓解腹泻的效果,尤其对旅行性腹泻的缓解和治疗产生积极作用。(The application discloses a probiotic composition capable of relieving or treating travel diarrhea and application thereof. The probiotic composition comprises bifidobacterium lactis Probio-M8 and lactobacillus plantarum. The probiotic composition is proved by tracking and detecting the effective microorganism content in the intestinal tract of the travelling crowd, and if the probiotic composite solid beverage can balance the intestinal microecology, the effect of relieving diarrhea is further achieved, and particularly, the probiotic composite solid beverage has a positive effect on relieving and treating the travelling diarrhea.)

1. A probiotic composition for alleviating or treating travel diarrhea, comprising: bifidobacterium lactis Probio-M8(Bifidobacterium lactis Probio-M8, Probio-M8) and Lactobacillus plantarum (Lactobacillus plantarum), wherein the preservation number of the Bifidobacterium lactis Probio-M8 is CGMCC No.18610, and the preservation number of the Lactobacillus plantarum is CGMCC No. 11446.

2. Use of the probiotic composition of claim 1 for the alleviation or treatment of travel diarrhoea.

3. A probiotic product for alleviating or treating travel diarrhea, comprising bifidobacterium lactis Probio-M8 of claim 1 and said lactobacillus plantarum.

4. The probiotic product according to claim 3, characterized in that it comprises a ready-to-use starter and functional probiotic fermented dairy products and nutraceuticals.

5. The probiotic product according to claim 3, characterized in that it comprises a soy, dairy or fruit-vegetable product produced using the Bifidobacterium lactis Probio-M8 and a starter of Lactobacillus plantarum.

6. The probiotic product according to claim 3, characterized in that it comprises a pharmaceutical product comprising Bifidobacterium lactis Probio-M8 and Lactobacillus plantarum, and, a pharmaceutical carrier and/or a pharmaceutical excipient.

7. A probiotic solid beverage for alleviating or treating travel diarrhea, comprising Bifidobacterium lactis Probio-M8 of claim 1 and said Lactobacillus plantarum.

Technical Field

The application relates to the technical field of biology, in particular to a probiotic composition capable of relieving or treating travel diarrhea and application thereof.

Background

Diarrhea is commonly called as diarrhea, and means that the frequency of defecation obviously exceeds the frequency of daily habit, the feces is thin, the moisture is increased, the daily defecation amount exceeds 200g, or the diarrhea contains undigested food, purulent blood and mucus. Diarrhea is clinically accompanied by symptoms such as defecation urgency, anal discomfort, incontinence and the like. Usually, infection with pathogens such as bacteria, viruses or parasites is the leading cause of diarrhea, also known as infectious diarrhea or gastroenteritis, and the occurrence and spread of infectious diarrhea is considered to be a result of poor hygiene. With the development of society, travel or business trip is one of the lifestyle needs associated with everyone. Studies have shown that "water and soil intolerance" is caused by travel, and the accompanying symptoms of diarrhea are not due to water and soil intolerance in the area of travel. The cause of this is infectious diarrhea, which is a special type. Over 90% of pathogens are bacteria, which are mainly from contaminated water and food and, when introduced into the body, can potentially reoccur hours to days. The treatment difficulty and the uncertainty factor of the travel diarrhea are higher than those of the common diarrhea. At present, the most common method for treating the travel diarrhea, namely the bacterial infectious diarrhea, in the market is antibiotic treatment, and the statistical data of the Chinese medical society show that the average usage rate of the antibiotics of the diarrhea patients in China is up to 84% every year, the balance of normal flora of intestinal tracts of the patients is greatly damaged by the use of the antibiotics, and fatal double infection is easy to occur.

Disclosure of Invention

The application aims to provide a probiotic composition capable of relieving or treating the travel diarrhea and application thereof, so as to solve the problem that the treatment of the diarrhea by antibiotics destroys the balance of normal flora in intestinal tracts and causes superinfection.

In a first aspect, there is provided a probiotic composition for alleviating or treating travel diarrhoea, comprising: bifidobacterium lactis Probio-M8(Bifidobacterium lactis Probio-M8, Probio-M8) and Lactobacillus plantarum (Lactobacillus plantarum). The Bifidobacterium lactis Probio-M8 is preserved in China general microbiological culture Collection center (CGMCC) with the preservation number of CGMCC No. 18610; classified and named as Bifidobacterium lactis (Bifidobacterium lactis); preservation time: 09 month and 20 days 2019; and (4) storage address: western road No.1, north west city of township, beijing, institute of microbiology, china academy of sciences; the survival of the strain was detected. The lactobacillus plantarum is preserved in the China general microbiological culture Collection center (CGMCC) with the preservation number of CGMCC No. 11446. Classified and named as Lactobacillus plantarum (Lactobacillus plantarum); preservation time: 24 days 09 month 2015; and (4) storage address: western road No.1, north west city of township, beijing, institute of microbiology, china academy of sciences; the survival of the strain was detected. This strain has been disclosed in patent publication No. CN 105779350B.

In a second aspect, there is provided the use of the probiotic composition in the alleviation or treatment of travelling diarrhoea.

In a third aspect, there is provided a probiotic product for alleviating or treating traveller's diarrhea, comprising said bifidobacterium lactis Probio-M8 and said lactobacillus plantarum.

Further, the probiotic product comprises a direct vat set starter and a functional probiotic fermented dairy product and a health product.

Further, the probiotic product comprises a bean product, a dairy product or a fruit and vegetable product which is produced by using the bifidobacterium lactis Probio-M8 and the lactobacillus plantarum leavening agent.

Further, the probiotic product comprises a medicine, wherein the medicine comprises bifidobacterium lactis Probio-M8 and lactobacillus plantarum, and a medicine carrier and/or a medicinal auxiliary material.

In a fourth aspect, a probiotic solid beverage capable of alleviating or treating travel diarrhea is provided, which comprises the bifidobacterium lactis Probio-M8 and the lactobacillus plantarum.

According to the technical scheme, the embodiment of the application discloses a probiotic composition capable of relieving or treating the travel diarrhea and application thereof. The probiotic composition comprises bifidobacterium lactis Probio-M8 and lactobacillus plantarum. The probiotic composition is proved by tracking and detecting the effective microorganism content in the intestinal tract of the travelling crowd, and if the probiotic composite solid beverage can balance the intestinal microecology, the effect of relieving diarrhea is further achieved, and particularly, the probiotic composite solid beverage has a positive effect on relieving and treating the travelling diarrhea.

Drawings

In order to more clearly illustrate the embodiments of the present application or the technical solutions in the prior art, the drawings needed to be used in the embodiments will be briefly described below, and it is obvious that the drawings in the following description are only some embodiments of the present application, and it is obvious for those skilled in the art to obtain other drawings without creative efforts.

Figure 1 is the frequency of defecation by the subject.

Detailed Description

The present application provides a probiotic composition for alleviating or treating travel diarrhea, comprising: bifidobacterium lactis Probio-M8(Bifidobacterium lactis Probio-M8, Probio-M8) and Lactobacillus plantarum (Lactobacillus plantarum).

The bifidobacterium lactis Probio-M8 is isolated from breast milk of healthy women and is a probiotic strain with good gastrointestinal fluid and bile salt tolerance. The Bifidobacterium lactis Probio-M8 is preserved in China general microbiological culture Collection center (CGMCC) with the preservation number of CGMCC No. 18610; classified and named as Bifidobacterium lactis (Bifidobacterium lactis); preservation time: 09 month and 20 days 2019; and (4) storage address: western road No.1, north west city of township, beijing, institute of microbiology, china academy of sciences; the survival of the strain was detected.

The lactobacillus plantarum can resist salmonella enteritidis infection, has good acid and bile salt resistance, and has a remarkable inhibiting effect on the growth of salmonella enteritidis. The lactobacillus plantarum is preserved in the China general microbiological culture Collection center (CGMCC) with the preservation number of CGMCC No. 11446. Classified and named as Lactobacillus plantarum (Lactobacillus plantarum); preservation time: 24 days 09 month 2015; and (4) storage address: western road No.1, north west city of township, beijing, institute of microbiology, china academy of sciences; the survival of the strain was detected. This strain has been disclosed in patent publication No. CN 105779350B.

The embodiments of the present application provide the use of the probiotic composition in the alleviation or treatment of travel diarrhoea.

The embodiment of the application provides a probiotic product capable of relieving or treating travel diarrhea, which comprises the bifidobacterium lactis Probio-M8 and the lactobacillus plantarum.

Further, the probiotic product comprises a direct vat set starter and a functional probiotic fermented dairy product and a health product.

Further, the probiotic product comprises a bean product, a dairy product or a fruit and vegetable product which is produced by using the bifidobacterium lactis Probio-M8 and the lactobacillus plantarum leavening agent.

Further, the probiotic product comprises a medicine, wherein the medicine comprises bifidobacterium lactis Probio-M8 and lactobacillus plantarum, and a medicine carrier and/or a medicinal auxiliary material.

The embodiment of the application provides a probiotic solid beverage capable of relieving or treating travel diarrhea, which comprises the bifidobacterium lactis Probio-M8 and the lactobacillus plantarum.

In order to demonstrate that the probiotic solid beverage containing the bifidobacterium lactis Probio-M8 and the lactobacillus plantarum can alleviate or treat the travelling diarrhea, the following experiments were performed.

Experimental example 1 establishment of clinical experiment of population suffering from travelling diarrhea through intervention of probiotic solid beverage

1. Human experiments of probiotic bifidobacterium lactis Probio-M8 and lactobacillus plantarum for intervening in treating travel diarrhea are carried out, under the condition of completely conforming to ethics, treatment studies are carried out on volunteers, and the experiments are divided into A, B, C, G groups, wherein the G group is a placebo group, and the A, B, C group is an experimental group. The screening criteria of the human experimental volunteers are shown in table 1, and the detailed grouping is shown in table 2.

2. The probiotic solid beverage for test is administered by dissolving in warm water, milk or orally, and is administered 1 time (1.0 × 10) after meal¹¹CFU/time), for 21 consecutive days.

3. The solid beverage comprises maltodextrin and apple powder, wherein the solid beverage comprises Bifidobacterium lactis Probio-M8 and Lactobacillus plantarum (Bifidobacterium lactis Probio-M8 and Lactobacillus plantarum) at equal ratio of 1.0 × 10¹¹CFU/time, once daily).

4. Two clinical data collections were performed at the beginning and end of the trial, respectively, and ANOVA analysis was performed using SAS software.

TABLE 1 screening criteria for human experiments

TABLE 2 detailed grouping